Role and mechanism underlying FoxO6 in skeletal muscle <em>in vitro</em> and <em>in vivo</em>

Zhang,Lei; Zhang,Yiyi; Zhou,Min; Wang,Shuang; Li,Tiane; Hu,Zhangyong; Jin,Chengwu

doi:10.3892/ijmm.2021.4976

Role and mechanism underlying FoxO6 in skeletal muscle in vitro and in vivo

Authors:
- Lei Zhang
- Yiyi Zhang
- Min Zhou
- Shuang Wang
- Tiane Li
- Zhangyong Hu
- Chengwu Jin
View Affiliations

Affiliations: Department of Endocrinology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, P.R. China, Department of Infection Disease, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610041, P.R. China, Department of General Surgery, Chengdu Fifth People's Hospital, The Fifth People's Hospital Affiliated with Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611130, P.R. China
Published online on: June 1, 2021 https://doi.org/10.3892/ijmm.2021.4976
Article Number: 143

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Skeletal muscle atrophy is a common feature of patients suffering with chronic infection and other systemic diseases, including acquired immunodeficiency syndrome, chronic kidney disease and cancer. Therefore, understanding the molecular basis of muscle loss is of importance. The majority of members of the forkhead box O (FoxO) family can induce skeletal muscle atrophy; however, the effect of FoxO6 on skeletal muscle is not completely understood. The present study investigated the role of FoxO6 in vitro and in vivo. Compared with the small interfering RNA (si)‑negative control (NC) group, C₂C₁₂ cell proliferation (Cell Counting Kit‑8 assay), myotube differentiation and myotube production were significantly decreased by FoxO6 knockdown, which was different from the known functions of other FoxO members. The immunofluorescence assay results demonstrated that si‑FoxO6 clearly downregulated the expression levels of myosin heavy chain (MyHC) in C₂C₁₂ myotubes compared with si‑NC. The western blotting results indicated that compared with the si‑NC group, FoxO6 knockdown induced C₂C₁₂ myotube atrophy by notably downregulating myoblast determination protein 1 (MyoD), mTOR and MyHC expression levels, and by markedly upregulating ubiquitin ligase (atrogin1) and muscle RING‑finger protein‑1 (MURF1) expression levels. Similarly, in an in vitro model of TNF‑α‑induced myotube atrophy, the western blotting results indicated that FoxO6 expression levels were decreased, whereas atrogin1, MURF1, FoxO1 and FoxO3a expression levels were increased compared with the control group. Therefore, the results indicated that, unlike FoxO1 or FoxO3a, FoxO6 maintained C₂C₁₂ myotubes and protected against atrophy. Consistent with the in vitro data, similar results were observed in vivo. Collectively, the results of the present study suggested that FoxO6 served a critical role in muscle cell metabolism in vitro and in vivo, and might serve as a promising therapeutic target for ameliorating skeletal muscle atrophy.

View Figures

View References

1	Sandri M: Autophagy in skeletal muscle. FEBS Lett. 584:1411–1416. 2010. View Article : Google Scholar : PubMed/NCBI
2	Lecker SH, Goldberg AL and Mitch WE: Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol. 17:1807–1819. 2006. View Article : Google Scholar : PubMed/NCBI
3	Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE and Goldberg AL: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18:39–51. 2004. View Article : Google Scholar : PubMed/NCBI
4	Fappi A, de Carvalho Neves J, Sanches LN, Silva PV, Sikusawa GY, Brandão TPC, Chadi G and Zanoteli E: Skeletal muscle response to deflazacort, dexamethasone and methylprednisolone. Cells. 8:4062019. View Article : Google Scholar :
5	Gupta A and Gupta Y: Glucocorticoid-Induced myopathy: Pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. 17:913–916. 2013. View Article : Google Scholar : PubMed/NCBI
6	Cohen S, Nathan JA and Goldberg AL: Muscle wasting in disease: Molecular mechanisms and promising therapies. Nat Rev Drug Discov. 14:58–74. 2015. View Article : Google Scholar : PubMed/NCBI
7	Jagoe RT and Goldberg AL: What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab. 4:183–190. 2001. View Article : Google Scholar
8	Jagoe RT, Lecker SH, Gomes M and Goldberg AL: Patterns of gene expression in atrophying skeletal muscles: The response to food deprivation. FASEB J. 16:1697–1712. 2002. View Article : Google Scholar : PubMed/NCBI
9	Gomes MD, Lecker SH, Jagoe RT, Navon A and Goldberg AL: Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA. 98:14440–14445. 2001. View Article : Google Scholar : PubMed/NCBI
10	Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, et al: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294:1704–1708. 2001. View Article : Google Scholar : PubMed/NCBI
11	Megeney LA, Kablar B, Garrett K, Anderson JE and Rudnicki MA: MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev. 10:1173–1183. 1996. View Article : Google Scholar : PubMed/NCBI
12	Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ and Yancopoulos GD: Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 3:1014–1019. 2001. View Article : Google Scholar : PubMed/NCBI
13	Agbulut O, Noirez P, Beaumont F and Butler-Browne G: Myosin heavy chain isoforms in postnatal muscle development of mice. Biol Cell. 95:399–406. 2003. View Article : Google Scholar : PubMed/NCBI
14	Hannenhalli S and Kaestner KH: The evolution of fox genes and their role in development and disease. Nat Rev Genet. 10:233–240. 2009. View Article : Google Scholar : PubMed/NCBI
15	Link W: Introduction to FOXO biology. Methods Mol Biol. 1890:1–9. 2019. View Article : Google Scholar
16	Monsalve M and Olmos Y: The complex biology of FOXO. Curr Drug Targets. 12:1322–1350. 2011. View Article : Google Scholar : PubMed/NCBI
17	Jacobs FM, van der Heide LP, Wijchers PJ, Burbach JPH, Hoekman MFM and Smidt MP: FoxO6, a novel member of the foxo class of transcription factors with distinct shuttling dynamics. J Biol Chem. 278:35959–35967. 2003. View Article : Google Scholar : PubMed/NCBI
18	Liu W, Li Y and Luo B: Current perspective on the regulation of FOXO4 and its role in disease progression. Cell Mol Life Sci. 77:651–663. 2020. View Article : Google Scholar
19	Reed SA, Sandesara PB, Senf SM and Judge AR: Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J. 26:987–1000. 2012. View Article : Google Scholar :
20	Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH and Goldberg AL: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117:399–412. 2004. View Article : Google Scholar : PubMed/NCBI
21	Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T, Mochida K, Hata T, Matsuda J, Aburatani H, et al: Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem. 279:41114–41123. 2004. View Article : Google Scholar : PubMed/NCBI
22	Xu J, Li RS, Workeneh B, Dong Y, Wang X and Zhaoyong Hu: Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int. 82:401–411. 2012. View Article : Google Scholar : PubMed/NCBI
23	Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH and Goldberg AL: FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metabol. 6:472–483. 2007. View Article : Google Scholar
24	Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Piccolo PD, Burden SJ, Lisi RD, Sandri C, Zhao JH, et al: Foxo3 controls autophagy in skeletal muscle in vivo. Cell Metabol. 6:458–471. 2007. View Article : Google Scholar
25	Moylan JS, Smith JD, Chambers MA, McLoughlin TJ and Reid MB: TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. Am J Physiol Cell Physiol. 295:C986–C993. 2008. View Article : Google Scholar : PubMed/NCBI
26	Hoekman MF, Jacobs FM, Smidt MP and Burbach JP: Spatial and temporal expression of FoxO transcription factors in the developing and adult murine brain. Gene Expr Patterns. 6:134–140. 2006. View Article : Google Scholar
27	Salih DA, Rashid AJ, Colas D, de la Torre-Ubieta L, Zhu RP, Morgan AA, Santo EE, Ucar D, Devarajan K, Cole CJ, et al: FoxO6 regulates memory consolidation and synaptic function. Genes Dev. 26:2780–2801. 2012. View Article : Google Scholar : PubMed/NCBI
28	Chung SY, Huang WC, Su CW, Lee KW, Chi HS, Lin CT, Chen ST, Huang KM, Tsai MS, Yu HP and Chen SL: FoxO6 and PGC-1α form a regulatory loop in myogenic cells. Biosci Rep. 33:e000452013. View Article : Google Scholar
29	Sun Z, da Fontoura CSG, Moreno M, Holton NE, Sweat M, Sweat Y, Lee MK, Arbon J, Bidlack FB, Thedens DR, et al: FoxO6 regulates hippo signaling and growth of the craniofacial complex. PLoS Genet. 14:e10076752018. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-(-Delta Delta C(T))method. Methods. 25:402–408. 2001. View Article : Google Scholar
31	Eley HL, Russell ST and Tisdale MJ: Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-alpha and angiotensin II by beta-hydroxy-beta-methylbutyrate. Am J Physiol Endocrinol Metab. 295:E1417–E1426. 2008. View Article : Google Scholar : PubMed/NCBI
32	Chen X, Wu Y, Yang T, Wei M, Wang Y, Deng X, Shen C, Li W, Zhang H, Xu W, et al: Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. J Cachexia Sarcopenia Muscle. 7:225–232. 2016. View Article : Google Scholar : PubMed/NCBI
33	Mandai S, Mori T, Nomura N, Furusho T, Arai Y, Kikuchi H, Sasaki E, Sohara E, Rai T, Uchida S, et al: WNK1 regulates skeletal muscle cell hypertrophy by modulating the nuclear localization and transcriptional activity of FOXO4. Sci Rep. 14:91012018. View Article : Google Scholar
34	Derde S, Hermans G, Derese I, Güiza F, Hedström Y, Wouters PJ, Bruyninckx F, D'Hoore A, Larsson L, Van den Berghe G and Vanhorebeek I: Muscle atrophy and preferential loss of myosin in prolonged critically ill patients. Crit Care Med. 40:79–89. 2012. View Article : Google Scholar
35	Banduseela V, Ochala J, Lamberg K, Kalimo H and Larsson L: Muscle paralysis and myosin loss in a patient with cancer cachexia. Acta Myol. 26:136–144. 2007.
36	Risson V, Mazelin L, Roceri M, Sanchez H, Moncollin V, Corneloup C, Richard-Bulteau H, Vignaud A, Baas D, Defour A, et al: Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J Cell Biol. 187:859–874. 2009. View Article : Google Scholar : PubMed/NCBI